In recent years, the interest of the scientific community in the immune system as it relates to cancer has greatly…
Browsing: Acute Lymphoblastic Leukemia
Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenia purpura (ITP), and there remains significant variability in clinical practice…
In this Key Insights activity, Drs. Corey J. Langer, MD and Joshua Bauml discuss the key take-home points from the…
Recent developments in research allowing for the DNA analysis of formalin-fixed samples have allowed for greater accessibility to tumor sample…
Proton beam therapy is a high energy, localized form of radiation therapy that has the potential to greatly improve the…
Recent research has demonstrated that a lot of information about a cancer can be elucidated from a formalin-fixed sample, as…
With the NHS opening two high energy proton beam centers next year, optimism is high in the medical community for…
Even though the UKs first high energy proton beam centers are yet to open, it is critical to look forward…
The NHS is opening its first two high energy proton beam therapy centers in 2018 and 2020, at great financial…
The dissemination and sharing of scientific knowledge is key to improving healthcare practices on a national and international scale. In…
Novel immunotherapies have great potential to improve the survival of cancer patients; however, new treatments must be introduced in a…
The early diagnosis of cancer is key to survival; however, with the many demands upon the NHS this can be…
CRUK is well known for scientific research; however, it also employs other channels to transition the results of this research…
The CRUK Facilitator programme is collaborating with community pharmacists to provide training and resources. In this interview, Gillian Phillips from…
The earlier cancer is diagnosed, the higher the chance of recovery. At the British Oncology Pharmacy Association (BOPA) 20th Annual…
Immunotherapy for acute myeloid leukemia (AML) is an exciting area, with clinical trials, including those that are first-in-human, showing promising…
There were impressive updates on venetoclax combination studies for elderly acute myeloid leukemia (AML) that are progressing at the American…
E-selectin is involved in the progression of acute myeloid leukemia (AML), playing a key role in angiogenesis, thus making it…
In this exciting interview from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Maria-Victoria…
SYK, which directly binds to and activates FLT3, has been implicated in the pathogenesis of B-cell malignancies, making it a…
There have been great advances in the targeting of FLT3 for acute myeloid leukemia (AML) in recent years, many of…
FLT3 ITD acute myeloid leukemia (AML) is associated with high rates of relapse, after which prognosis is very poor. Thus,…
There are now several novel drugs targeting the protein kinase FLT3 in patients with acute myeloid leukemia (AML). Here, Keith…
Recent data have suggested that chronic lymphocytic leukemia (CLL) patients, in particular those with mutated immunoglobulin heavy chain genes, can…
Ibrutinib is associated with a range of side effects, including increased bruising, TKI ecchymosis, low-grade bleeding and hemorrhage. This has…
A range of chronic lymphocytic leukemia (CLL) research was presented at the American Society of Hematology (ASH) 2017 Annual Meeting…
Despite the combination of ibrutinib and rituximab not significantly affecting progression-free survival in patients with chronic lymphocytic leukemia (CLL), many…
The targeted agent ibrutinib has been tested as a first-line monotherapy in elderly chronic lymphocytic leukemia (CLL) in the RESONATE-2…
Decitabine, a DNA methyltransferase (DNMT) inhibitor, which is given to patients with myelodysplastic syndromes (MDS), is classically administered intravenously. Now,…
Clinical access to new technologies, such as next-generation sequencing (NGS), can revolutionize the treatment of cancer. In this interview, Guillermo…
Pracinostat is a histone deacetylase (HDAC) inhibitor that has demonstrated very promising efficacy in acute myeloid leukemia (AML) and myelodysplastic…
In cutaneous T-cell lymphoma (CTCL) miR-155 has been shown to be upregulated. Here, Christiane Querfeld, MD, PhD, of City of…
Immune checkpoint inhibitors have now entered the treatment landscape for cutaneous T-cell lymphoma (CTCL). In this interview, Christiane Querfeld, MD,…
CAR T-cell therapies have exhibited strong and durable responses in several hematological malignancies thus far. Now bb2121, an anti-BCMA CAR…
For CAR T-cell therapy to become mainstream, the management of related toxicities needs to be addressed. Speaking from the American…
Immunotherapy for lymphoid malignancies progressed dramatically in 2017, with FDA approval of two CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel.…
The Phase I/II trial ZUMA-1 (NCT02348216) was pivotal for CAR T-cell development. In this interview, Yi Lin, MD, PhD, of…
The ground-breaking PRECISION-Panc project aims to speed up scientific discovery to improve the survival rates of patients with pancreatic cancer.…
The imminent pancreatic cancer trial PRIMUS001 (ISRCTN75002153) has the potential to personalize therapy for patients with pancreatic cancer. In this…
This is an exciting time for pancreatic cancer research, with advances in immunotherapy, genomic sequencing and druggable targets. What the…
There is a necessity for further clinical trials and research into pancreatic cancer in order to improve patient outcomes. In…
Although progress has been made in the treatment of pancreatic cancer, further research is required to identify novel therapeutic options…
How can patients navigate between treatment options with all of the recent breakthroughs in myeloma therapy? Dr. Guilherme Perini, a…
Where is lymphoma treatment today? Stay in the know with Brazilian hematologist Dr. Guilherme Perini as he discusses advances in…
The landscape of myeloma care is constantly evolving with the development of new research and treatment. While advances in myeloma…
What have researchers discovered about ROR1 and its role in targeted CLL therapies? Andrew Schorr hosts coverage from the 2017…
Can todays medicines be used together to treat CLL more effectively? CLL expert Dr. Michael Choi of UC San Diego…
Where do things stand now with personalizing myeloma therapy to a patients genetic profile? At the American Society of Hematology…
The first relatively long-term CAR T-cell trial follow-up data came out at the American Society of Hematology (ASH) 2017 Annual…
The right balance of T-cell expansion needs to be achieved in order to obtain the optimal response to CAR T-cell…